Kimihiro Yamashita (1), Yasufumi Kataoka (1,#), Mihoko N.-Nakashima (2), Yasuko S.-Yamashita (1), Hirofumi Tanabe (3), Hiroaki Araki (4), Masami Niwa (1) and Kohtaro Taniyama (1,*)
Departments of (1) Pharmacology and (2) Hospital Pharmacy, Nagasaki University School of Medicine, 1-12-4 Sakamoto, Nagasaki 852, Japan (3) Pharmacological Research Department, Pharmaceuticals Development Research Laboratories, Teijin Institute for Bio-medical Research, Teijin Ltd., Tokyo 191, Japan (4) Pharmacology Laboratory, Pharmaceutical Research Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama 330, Japan (#) Present address: Department of Hospital Pharmacy, Faculty of Medicine, Kyushu University, Fukuoka 812, Japan (*) To whom correspondence should be addressed.
Abstract: TTC-909 is a newly developed isocarbacyclin methyl ester (TEI-9090) incorporated in lipid microspheres. The neuroprotective effect of TTC-909 was histologically examined in the pyramidal cell layer of the hippocampus CA1 subfield 7 days after transient forebrain ischemia using stroke-prone spontaneously hypertensive rats. TTC-909, given intravenously 10 min after the transient forebrain ischemia, dose-dependently protected against ischemia-related delayed neuronal death. The blood pressure remained unchanged following TTC-909 administration. This finding suggests that TTC-909 has a neuroprotective action on ischemic delayed neuronal death in the hippocampus.
Ischemia-related delayed neuronal death, Prostacyclin analogue,
Stroke-prone spontaneously hypertensive rat
[Back to TOC]